BiomX (PHGE) Accounts Payables (2018 - 2026)
BiomX's (PHGE) quarterly Accounts Payables came in at $1.1 million in Q2 2026, down 60.47% year-over-year from $2.9 million in Q2 2025, and up 56.53% quarter-over-quarter from $720000.0 in Q1 2026.
Analysis
BiomX (PHGE) Accounts Payables (2018 - 2026) Analysis & Trends
BiomX has disclosed Accounts Payables across 9 years of filings, most recently posting $1.1 million for Q2 2026.
- In Q2 2026, Accounts Payables fell 60.47% year-over-year to $1.1 million; the TTM figure through Jun 2026 stood at $1.1 million (down 60.47% YoY), while the FY2025 annual figure was $3.1 million, down 40.63% from the prior year.
- Accounts Payables came in at $1.1 million for Q2 2026 at BiomX, up from $720000.0 in the prior quarter.
- In the past five years, Accounts Payables ranged from a high of $5.5 million in Q3 2023 to a low of $720000.0 in Q1 2026.
- Average Accounts Payables over 5 years is $2.9 million, with a median of $3.0 million recorded in 2025.
- Year-over-year, Accounts Payables jumped 209.04% in 2023 and slumped 82.9% in 2026.
- Over 5 years, Accounts Payables stood at $2.2 million in 2022, then soared by 55.53% to $3.3 million in 2023, then jumped by 57.15% to $5.3 million in 2024, then plunged by 40.63% to $3.1 million in 2025, then plunged by 63.88% to $1.1 million in 2026.
- Per Business Quant data, the three most recent Accounts Payables figures were $1.1 million in Q2 2026, $720000.0 in Q1 2026, and $3.1 million in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.73 Bn | 197.74 Bn | 7.24 Bn | 2.87 Bn |
| 2 | Gilead Sciences | 180.92 Bn | 177.74 Bn | 6.22 Bn | 674.00 Mn |
| 3 | Vertex Pharmaceuticals | 132.16 Bn | 124.30 Bn | 2.84 Bn | 429.50 Mn |
| 4 | Regeneron Pharmaceuticals | 82.89 Bn | 74.90 Bn | 3.93 Bn | 1.16 Bn |
| 5 | Argenx Se | 61.41 Bn | 56.23 Bn | 1.37 Bn | 1.52 Bn |
| 6 | Moderna | 53.99 Bn | 48.85 Bn | 52.00 Mn | 167.00 Mn |
| 7 | Alnylam Pharmaceuticals | 34.48 Bn | 31.18 Bn | 992.69 Mn | 108.02 Mn |
| 8 | Biogen | 31.15 Bn | 29.86 Bn | 1.96 Bn | 403.90 Mn |
| 9 | Roivant Sciences | 30.05 Bn | 30.05 Bn | 1.16 Mn | 25.08 Mn |
| 10 | BiomX | 17.33 Mn | 16.75 Mn | 97,000.00 | 1.13 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 1.13 Mn |
| Mar 31, 2026 | 720,000.00 |
| Dec 31, 2025 | 3.12 Mn |
| Sep 30, 2025 | 2.42 Mn |
| Jun 30, 2025 | 2.85 Mn |
| Mar 31, 2025 | 4.21 Mn |
| Dec 31, 2024 | 5.26 Mn |
| Sep 30, 2024 | 5.07 Mn |
| Jun 30, 2024 | 3.24 Mn |
| Mar 15, 2024 | 3.67 Mn |
| Dec 31, 2023 | 3.34 Mn |
| Sep 30, 2023 | 5.50 Mn |
| Jun 30, 2023 | 3.39 Mn |
| Mar 31, 2023 | 1.36 Mn |
| Dec 31, 2022 | 2.15 Mn |
| Sep 30, 2022 | 1.78 Mn |
| Jun 30, 2022 | 1.66 Mn |
| Mar 31, 2022 | 1.40 Mn |
| Dec 31, 2021 | 2.80 Mn |
| Sep 30, 2021 | 1.88 Mn |